Loading…
Kalaris Therapeutics, Inc. is projected to decline to $4.10 by 2027, a -8% move from its current price of $4.44. KLRS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.29 | $4.44 | $4.60 | +0.04% |
| Jul 13 | $4.23 | $4.44 | $4.67 | +0.09% |
| Jul 14 | $4.19 | $4.45 | $4.72 | +0.13% |
| Jul 15 | $4.15 | $4.45 | $4.76 | +0.17% |
| Jul 16 | $4.12 | $4.45 | $4.81 | +0.21% |
| Jul 17 | $4.09 | $4.45 | $4.84 | +0.26% |
| Jul 18 | $4.07 | $4.45 | $4.88 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.07 | $4.45 | $4.88 | +0.30% |
| Week 2 | $3.93 | $4.47 | $5.08 | +0.60% |
| Week 3 | $3.83 | $4.48 | $5.24 | +0.90% |
| Week 4 | $3.75 | $4.49 | $5.39 | +1.21% |
| Week 5 | $3.68 | $4.51 | $5.52 | +1.51% |
| Week 6 | $3.62 | $4.52 | $5.65 | +1.82% |
| Week 7 | $3.56 | $4.53 | $5.77 | +2.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on retinal diseases. It develops TH103, a clinical-stage anti-VEGF drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2.
The company was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey. KLRS operates in the Healthcare sector and is focused on developing treatments for prevalent retinal diseases, aiming to advance therapies that address exudative and neovascular retinal conditions.
KLRS is a small-cap biopharmaceutical with a current price of $4.53 and a market capitalization of $107.78M. It ranks 4195 by market cap among publicly traded entities. The stock currently sits in a narrow price context, with a 30-day range of $3.55 to $5.78.
Forecasts for 2026 place KLRS at an average price of $4.53 with a min of $4.07 and a max of $5.99, and aROI of 0, indicating a neutral near-term outlook. Looking further ahead, the multi-year forecast shows a bullish path: 2030 with an average of $5.49 (min $3.82, max $8.56, ROI 21.3), 2040 with an average of $6.89 (ROI 52.1), and 2050 with an average of $15.08 (ROI 233). These figures imply meaningful upside over the long run while underscoring notable variability in intermediate years.
A major floor 23.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 18.7% above — a clean break opens room to run.
A major ceiling 125.2% above — clearing it would confirm fresh momentum.
Key KLRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KLRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.62 | Sell | $4.55 | Sell |
| MA 10 | $4.50 | Sell | $4.53 | Sell |
| MA 20 | $4.46 | Sell | $4.54 | Sell |
| MA 50 | $4.75 | Sell | $4.94 | Sell |
| MA 100 | $6.22 | Sell | $5.65 | Sell |
| MA 200 | $6.68 | Sell | $6.38 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.21 | Neutral |
| Stoch RSI (14) | 53.00 | Neutral |
| CCI (20) | -7.96 | Neutral |
| Williams %R (14) | -51.32 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -0.67 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 48.68 | Neutral |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 54.62 | Neutral |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 4.64 | Sell |
| ADX (14) | 14.98 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 50, reflecting balanced momentum.
The stock’s short-term moving averages show a SMA50 of $4.92 and a SMA200 of $6.68, creating near-term resistance around $5.27 and support at $4.07.
The 30-day price range runs from $3.55 to $5.78, and annualized volatility is reported at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.07 | $4.44 | $5.78 | 0% | Neutral | |
| $3.18 | $4.10 | $5.63 | -8% | Neutral | |
| $2.91 | $3.88 | $5.57 | -13% | Neutral | |
| $3.42 | $4.71 | $7.00 | +6% | Neutral | |
| $3.77 | $5.33 | $8.16 | +20% | Bullish | |
| $3.73 | $5.40 | $8.47 | +22% | Bullish | |
| $3.59 | $5.32 | $8.55 | +20% | Neutral | |
| $3.46 | $5.25 | $8.60 | +18% | Neutral | |
| $3.40 | $5.25 | $8.77 | +18% | Neutral | |
| $3.42 | $5.40 | $9.17 | +22% | Bullish | |
| $3.87 | $6.69 | $12.22 | +51% | Bullish | |
| $7.03 | $14.33 | $29.06 | +223% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.07 | $4.44 | $5.25 | +0.00% |
| August 2026 | $3.70 | $4.39 | $5.39 | -1.02% |
| September 2026 | $3.85 | $4.62 | $5.74 | +5.06% |
| October 2026 | $3.86 | $4.66 | $5.86 | +0.94% |
| November 2026 | $3.71 | $4.51 | $5.72 | -3.28% |
| December 2026 | $3.68 | $4.51 | $5.78 | +0.02% |
Click any year to see its month-by-month KLRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KLRS is projected to trade between $4.07 and $5.78, averaging $4.44 — a potential gain of 0% from today's $4.44. A consolidation phase looks the most probable path here.
Kalaris Therapeutics, Inc.'s 2027 outlook centres on $4.10, within a $3.18 to $5.63 range. That is -8% versus the projected 2026 average. That marks a -8% change versus current levels. Price action looks broadly range-bound.
By 2028, KLRS could reach as high as $5.57, with a base case around $3.88 and support toward $2.91 — roughly -13% from $4.44. A consolidation phase looks the most probable path here.
Expect KLRS to range from $3.42 to $7.00 through 2029. The $4.71 average target implies a +6% move from current prices. That is up +21% on the projected 2028 average. Price action looks broadly range-bound.
The KLRS price prediction for 2030 points to an average of $5.33 (low $3.77, high $8.16) — a potential gain of +20% on today's $4.44. Buyers look set to stay in control over this stretch.
In 2031, KLRS is projected to trade between $3.73 and $8.47, averaging $5.40 — a potential gain of +22% from today's $4.44. That is up +1% on the projected 2030 average. Momentum favours further upside here.
Kalaris Therapeutics, Inc.'s 2032 outlook centres on $5.32, within a $3.59 to $8.55 range. That is -1% versus the projected 2031 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, KLRS could reach as high as $8.60, with a base case around $5.25 and support toward $3.46 — roughly +18% from $4.44. Price action looks broadly range-bound.
Expect KLRS to range from $3.40 to $8.77 through 2034. The $5.25 average target implies a +18% move from current prices. That is up 0% on the projected 2033 average. A consolidation phase looks the most probable path here.
The KLRS price prediction for 2035 points to an average of $5.40 (low $3.42, high $9.17) — a potential gain of +22% on today's $4.44. Momentum favours further upside here.
In 2040, KLRS is projected to trade between $3.87 and $12.22, averaging $6.69 — a potential gain of +51% from today's $4.44. That is up +24% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Kalaris Therapeutics, Inc.'s 2050 outlook centres on $14.33, within a $7.03 to $29.06 range. That is up +114% on the projected 2040 average. That marks a +223% change versus current levels. Momentum favours further upside here.
Investing $1,000 in KLRS today (≈ 225.225225 KLRS) could be worth
$3,228.18
+$2,228.18 (+223%) by 2050 · US Dollar
Based on the average projected KLRS price of $14.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KLRSwould be worth at today's price.
$1,000 invested in KLRS on Jul 10, 2025 (≈ 400 KLRS) would be worth
$1,776
+$776 (+77.6%) today · 1.78× · US Dollar
Based on a KLRS entry price of $2.5 vs. today's $4.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.75 | $934.74 | -6.5% |
| 1 month ago | $4.16 | $1,067.31 | +6.7% |
| 3 months ago | $6.3 | $704.76 | -29.5% |
| 6 months ago | $8.84 | $502.26 | -49.8% |
| 1 year ago | $2.5 | $1,776 | +77.6% |
| All time (5.0y) ago | $434.7 | $10.21 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KLRS forecast.
Our base-case forecast reaches $8.90 around 2050.
Implied market cap at $8.90: $211.75M
The multi-year outlook progresses from a neutral early period to a bullish long horizon. In 2030 the average price is projected at $5.49 with a min of $3.82 and a max of $8.56, and a ROI of 21.3, with a bullish sentiment. The trajectory continues with 2031 averaging $5.51 and 2032 averaging $5.59, both bearing bullish sentiment and positive ROIs (21.7 and 23.3 respectively).
By 2040 the forecast shows an average of $6.89 and a ROI of 52.1, with bullish sentiment continuing. In 2050 the average is projected at $15.08 and a ROI of 233, with a bullish sentiment; the max could reach $31.52. These long-range figures suggest substantial upside potential relative to the current level, tempered by volatility and timing risk.
These are estimates, not guarantees, and actual results will depend on market conditions, clinical outcomes, and other factors affecting the biotechnology sector.
Tap a question to reveal the answer.
2030 min $3.82, avg $5.49, max $8.56; ROI 21.3; sentiment BULLISH.
Near term is NEUTRAL with 2026 avg $4.53 and ROI 0. Longer term shows BULLISH sentiment with 2030 avg $5.49, 2040 avg $6.89 and 2050 avg $15.08, with ROIs of 21.3, 52.1 and 233.
Yes, the forecast max reaches $12.92 in 2040 and $31.52 in 2050, while earlier years top out below $10 (e.g., 2030 max $8.56, 2032 max $9.16, 2035 max $9.87).
Current price is $4.53 and market cap is $107.78M.
The 30-day range is $3.55 to $5.78.
Kalaris Therapeutics, Inc. Community Discussion
0Share your Kalaris Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.